Innovation payment schemes

In late November 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for two completed projects. The projects were dedicated to relieving the burden of emergency rooms and improving infection surveillance in nursing homes.

On November 29, 2024, the Ministry of Health and Access to Care published an Order outlining the requirements for application files to request coverage of innovative biology or pathology procedures within the new RIHN 2.0 framework. The Order concerns the application file model and list of supporting documents for coverage requests

On November 21, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that a total of fifty applications for Innovation Funding for the new forms of care in one- and two-stage procedures were accepted.

In November 2024, the Dutch Healthcare Authority (NZa) published an updated regulation and policy framework for small-scale experiments to introduce innovations, which will enter into force on January 01, 2025. The small-scale experiments for introducing innovations apply to innovative medical procedures that improve the organization and provision of patient care (including online consultation, telemonitoring, home neuromodulation, school counseling, etc.) but do not have enough evidence to obtain coverage within basic health insurance.

In September 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that received a subsidy under the "Subsidy scheme for promising care" in 2024 for research on the cost-effectiveness of cold plasma therapy for diabetic foot or venous leg wounds and intranasal mesenchymal stem cells in newborns with hypoxic-ischemic brain damage.

On September 2, 2024, the French Ministry of Health released further details on the renewed support for innovation in medical biology and anatomopathology procedures via the Repository of Innovative Services outside the Nomenclature of biology and anatomopathology (RIHN) 2.0 including criteria for application.

In mid-August 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another four completed projects. The projects were dedicated to the topics of support for families with a parent suffering from cancer, modeling routine risk screening in children, reducing problematic media use, promoting treatment motivation in people with computer game addiction and Internet addiction, and follow-up care for gestational diabetes.

In late June – mid-July 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of care concept for patients with hidradenitis suppurativa (acne inversa), the use of webcams in neonatal intensive care units, and improving the pharmacovigilance of innovative therapies.

On May 27, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that ninety-one applications (project ideas) for innovation funding of the projects for new forms of care were received.

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of booster vaccination against meningococci of serogroup C, reduction of antibiotic resistance, and dual pilot structure for diagnosis clarification in centers for rare diseases.

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that forty-eight applications for innovation funding of healthcare research projects were accepted.

On April 22, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that fourteen applications for innovation funding of development or further development of the clinical guidelines were accepted.